Popular drugs for weight loss are now being prescribed to kids as young as 12. It’s been nearly two years since the FDA ...

A recent study showed that well-known diabetes and weight loss drugs such as Ozempic and Wegovy do not raise the risk of ...

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s ...

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss ...

Thousands celebrate the rapid results of weight loss injections. But a new analysis reveals a harsh truth few are prepared ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.